PL2205620T3 - Bezpostaciowa forma (11beta,16alfa)-9-fluoro-11-hydroksy-16,17-[(1-metyloetylideno)bis(oksy)]-21-[[4-[(nitrooksy)metylo]benzoilo]oksy]pregnano-1,4-dieno-3,20-dionu” - Google Patents

Bezpostaciowa forma (11beta,16alfa)-9-fluoro-11-hydroksy-16,17-[(1-metyloetylideno)bis(oksy)]-21-[[4-[(nitrooksy)metylo]benzoilo]oksy]pregnano-1,4-dieno-3,20-dionu”

Info

Publication number: PL2205620T3
Authority: PL; Poland
Prior art keywords: oxy; nitrooxy; amorphous form; methylethyliden; 16alpha
Prior art date: 2007-10-25

Application number

PL08841744T

Other languages

English (en)

Inventor

Luis Anglada

Carlos Albet

Antonio Guglietta

Original Assignee

Ferrer Int

Nicox Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-25

Filing date

2008-10-23

Publication date

2011-10-31

2008-10-23 Application filed by Ferrer Int, Nicox Sa filed Critical Ferrer Int

2011-10-31 Publication of PL2205620T3 publication Critical patent/PL2205620T3/pl

Links

125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 title abstract 2
-1 1-methylethyliden Chemical class 0.000 title 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003246 corticosteroid Substances 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

PL08841744T 2007-10-25 2008-10-23 Bezpostaciowa forma (11beta,16alfa)-9-fluoro-11-hydroksy-16,17-[(1-metyloetylideno)bis(oksy)]-21-[[4-[(nitrooksy)metylo]benzoilo]oksy]pregnano-1,4-dieno-3,20-dionu” PL2205620T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ES200702796A ES2324007A1 (es)	2007-10-25	2007-10-25	Una forma amorfa de un compuesto antiinflamatorio.
EP08841744A EP2205620B1 (en)	2007-10-25	2008-10-23	Amorphous form of (11beta,16alpha)-9-fluoro-11-hydroxy-16,17-[(1-methylethyliden)bis(oxy)]-21-[[4- [(nitrooxy)methyl]benzoyl]oxy]-pregna-1,4-dien-3,20-dione
PCT/EP2008/064387 WO2009053439A2 (en)	2007-10-25	2008-10-23	An amorphous form of an anti-inflammatory compound

Publications (1)

Publication Number	Publication Date
PL2205620T3 true PL2205620T3 (pl)	2011-10-31

Family

ID=40377713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08841744T PL2205620T3 (pl)	2007-10-25	2008-10-23	Bezpostaciowa forma (11beta,16alfa)-9-fluoro-11-hydroksy-16,17-[(1-metyloetylideno)bis(oksy)]-21-[[4-[(nitrooksy)metylo]benzoilo]oksy]pregnano-1,4-dieno-3,20-dionu”

Country Status (19)

Country	Link
US (1)	US20100261691A1 (pl)
EP (1)	EP2205620B1 (pl)
JP (1)	JP2011500762A (pl)
KR (1)	KR20100091159A (pl)
CN (1)	CN101861327B (pl)
AT (1)	ATE505477T1 (pl)
AU (1)	AU2008316471A1 (pl)
BR (1)	BRPI0818822A2 (pl)
CA (1)	CA2703441A1 (pl)
CY (1)	CY1112540T1 (pl)
DE (1)	DE602008006244D1 (pl)
DK (1)	DK2205620T3 (pl)
ES (2)	ES2324007A1 (pl)
MX (1)	MX2010004423A (pl)
PL (1)	PL2205620T3 (pl)
PT (1)	PT2205620E (pl)
RU (1)	RU2010120844A (pl)
SI (1)	SI2205620T1 (pl)
WO (1)	WO2009053439A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2011001119A (es) *	2008-07-31	2011-03-02	Nicox Sa	Glucocorticoides unidos a esteres de nitrato por medio de un enlazador aromatico en la posicion 21 y su uso en oftalmololgia.
ES2359708B1 (es) *	2009-11-16	2012-03-30	Ferrer Internacional S.A.	Procedimiento de preparación de la (11beta,16alfa)-9-fluoro-11-hidroxi-16,17-[1-metil-etilidenebis(oxi)]-21-[1-oxo-[4-(nitrooximetil)benzoxi]]preña-1,4-dien-3,20-diona.
RU2629601C1 (ru) *	2016-11-03	2017-08-30	Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Казанская государственная медицинская академия" Министерства здравоохранения Российской Федерации	Способ лечения больных красным плоским лишаем
RU2709534C1 (ru) *	2018-07-12	2019-12-18	Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России)	Способ лечения хронических дерматозов

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1312115B1 (it) *	1999-06-24	2002-04-04	Nicox Sa	Composti amorfi e relative composizioni farmaceutiche
US8313504B2 (en) *	2000-09-18	2012-11-20	Cordis Corporation	Foam matrix embolization device
ITMI20020148A1 (it) *	2002-01-29	2003-07-29	Nicox Sa	Nuovi corticosteroidi
EP1336602A1 (en) *	2002-02-13	2003-08-20	Giovanni Scaramuzzino	Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
IL154370A0 (en) *	2003-02-10	2003-09-17	Chemagis Ltd	Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US20060045850A1 (en) *	2004-08-30	2006-03-02	Qpharma, Llc	Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
CN102134269A (zh) *	2005-09-02	2011-07-27	尼科克斯公司	糖皮质激素硝酰氧基衍生物

2007
- 2007-10-25 ES ES200702796A patent/ES2324007A1/es not_active Withdrawn
2008
- 2008-10-23 WO PCT/EP2008/064387 patent/WO2009053439A2/en not_active Ceased
- 2008-10-23 DE DE602008006244T patent/DE602008006244D1/de active Active
- 2008-10-23 PL PL08841744T patent/PL2205620T3/pl unknown
- 2008-10-23 EP EP08841744A patent/EP2205620B1/en not_active Not-in-force
- 2008-10-23 PT PT08841744T patent/PT2205620E/pt unknown
- 2008-10-23 AT AT08841744T patent/ATE505477T1/de active
- 2008-10-23 CN CN2008801131050A patent/CN101861327B/zh not_active Expired - Fee Related
- 2008-10-23 US US12/739,131 patent/US20100261691A1/en not_active Abandoned
- 2008-10-23 SI SI200830287T patent/SI2205620T1/sl unknown
- 2008-10-23 MX MX2010004423A patent/MX2010004423A/es active IP Right Grant
- 2008-10-23 RU RU2010120844/04A patent/RU2010120844A/ru not_active Application Discontinuation
- 2008-10-23 AU AU2008316471A patent/AU2008316471A1/en not_active Abandoned
- 2008-10-23 KR KR1020107008681A patent/KR20100091159A/ko not_active Withdrawn
- 2008-10-23 JP JP2010530461A patent/JP2011500762A/ja active Pending
- 2008-10-23 DK DK08841744.9T patent/DK2205620T3/da active
- 2008-10-23 CA CA2703441A patent/CA2703441A1/en not_active Abandoned
- 2008-10-23 BR BRPI0818822 patent/BRPI0818822A2/pt not_active IP Right Cessation
- 2008-10-23 ES ES08841744T patent/ES2364953T3/es active Active
2011
- 2011-07-12 CY CY20111100675T patent/CY1112540T1/el unknown

Also Published As

Publication number	Publication date
WO2009053439A2 (en)	2009-04-30
EP2205620A2 (en)	2010-07-14
WO2009053439A3 (en)	2009-07-16
DK2205620T3 (da)	2011-07-25
ES2364953T3 (es)	2011-09-19
AU2008316471A1 (en)	2009-04-30
MX2010004423A (es)	2010-09-10
EP2205620B1 (en)	2011-04-13
SI2205620T1 (sl)	2011-08-31
KR20100091159A (ko)	2010-08-18
CY1112540T1 (el)	2015-12-09
CA2703441A1 (en)	2009-04-30
PT2205620E (pt)	2011-07-12
ATE505477T1 (de)	2011-04-15
DE602008006244D1 (de)	2011-05-26
US20100261691A1 (en)	2010-10-14
JP2011500762A (ja)	2011-01-06
RU2010120844A (ru)	2011-11-27
CN101861327B (zh)	2012-10-31
BRPI0818822A2 (pt)	2015-04-22
CN101861327A (zh)	2010-10-13
ES2324007A1 (es)	2009-07-28

Publication	Publication Date	Title
SI2097437T1 (sl)	2015-10-30	Uporaba pregnanskih in androstanskih steroidov za izdelavo farmacevtskega sestavka za zdravljenje obolenj ožs-ja
WO2008057420A3 (en)	2008-10-09	Extended triterpene derivatives
BR112013002601A2 (pt)	2016-06-07	corticosteróides para o tratamento de dor em articulação
WO2010091067A3 (en)	2010-10-07	Derivatives of [1, 3] oxazin- 2-one useful for the treatment of metabolic diseases such as lipid disorders
EA201201403A1 (ru)	2013-04-30	Очень низкодозированные твердые пероральные лекарственные формы для гзт
UA94909C2 (ru)	2011-06-25	Фармацевтическая композиция нейроактивного стероида и ее применение
MX2011011126A (es)	2012-04-02	Composiciones y metodos para tratar quemaduras.
WO2008012338A3 (en)	2009-01-08	Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
DK1845994T3 (da)	2009-05-04	Kombination af methylxanthinforbindelser og steroider til at behandle kroniske luftvejssygdomme
AR072805A1 (es)	2010-09-22	Composiciones intranasales formas galenicas y metodos de tratamiento.
NZ589444A (en)	2013-03-28	NON-HORMONAL STEROID MODULATORS OF NF-Kappa B FOR TREATMENT OF DISEASE
WO2011059969A3 (en)	2011-09-22	Mammalian metabolites of steroids
PL2205620T3 (pl)	2011-10-31	Bezpostaciowa forma (11beta,16alfa)-9-fluoro-11-hydroksy-16,17-[(1-metyloetylideno)bis(oksy)]-21-[[4-[(nitrooksy)metylo]benzoilo]oksy]pregnano-1,4-dieno-3,20-dionu”
MX2009009838A (es)	2010-01-15	Esteres de acidos grasos de glucocorticoides como agentes antiinflamatorios y anti-cancer.
WO2009001209A8 (en)	2009-03-26	Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
UY29779A1 (es)	2006-12-29	Nitrooxi derivados de esteroides
BR112012029697A2 (pt)	2016-08-02	polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias
NO20075758L (no)	2008-01-10	Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin
MX2010004513A (es)	2010-08-02	Proceso de obtencion de un extracto estandarizado, extracto obtenido, composicion farmaceutica, metodo de tratamiento y uso de dicho extracto.
BRPI0607795A2 (pt)	2009-06-13	compostos antiinflamatórios
JP2008533079A5 (pl)	2009-04-16
NZ588470A (en)	2012-12-21	Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases
WO2009037584A3 (en)	2011-04-28	Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
WO2009045054A3 (en)	2009-05-22	A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof
AR070302A1 (es)	2010-03-31	Composicion farmaceutica de un sistema de liberacion vaginal de esteroides